These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11306964)

  • 1. T cytotoxic 1 and T cytotoxic 2 CD8 T cells both inhibit IgE responses.
    Thomas MJ; MacAry PA; Noble A; Askenase PW; Kemeny DM
    Int Arch Allergy Immunol; 2001; 124(1-3):187-9. PubMed ID: 11306964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation.
    Thomas MJ; Noble A; Sawicka E; Askenase PW; Kemeny DM
    J Immunol; 2002 Jan; 168(1):216-23. PubMed ID: 11751965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE.
    MacAry PA; Holmes BJ; Kemeny DM
    J Immunol; 1998 Jan; 160(2):580-7. PubMed ID: 9551891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An essential role for IL-18 in CD8 T cell-mediated suppression of IgE responses.
    Salagianni M; Wong KL; Thomas MJ; Noble A; Kemeny DM
    J Immunol; 2007 Apr; 178(8):4771-8. PubMed ID: 17404257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells.
    Holmes BJ; MacAry PA; Noble A; Kemeny DM
    Eur J Immunol; 1997 Oct; 27(10):2657-65. PubMed ID: 9368623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tc2 cells respond to soluble antigen in the respiratory tract and induce lung eosinophilia and bronchial hyperresponsiveness.
    Sawicka E; Noble A; Walker C; Kemeny DM
    Eur J Immunol; 2004 Sep; 34(9):2599-608. PubMed ID: 15307192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
    Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J
    Immunology; 2007 Feb; 120(2):148-59. PubMed ID: 17274112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
    Vinay DS; Kwon BS
    Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ tumor-specific Tc cells primed in vivo or in vitro against the BALB/c plasmacytoma ADJ-PC-5 use the same TcR V beta families but display distinct TC1 or TC2 characteristics.
    Becker C; Kölsch E; Pauels HG
    Immunobiology; 1997 Jun; 197(1):16-30. PubMed ID: 9241528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
    Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
    J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
    Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
    Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
    Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Th2 responses and allergic inflammation through bystander activation of CD8+ T lymphocytes in early life.
    Dubois A; Deruytter N; Adams B; Kanda A; Delbauve S; Fleury S; Torres D; François A; Pétein M; Goldman M; Dombrowicz D; Flamand V
    J Immunol; 2010 Jul; 185(2):884-91. PubMed ID: 20562264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
    Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
    J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.